Zacks: Analysts Set $4.50 Price Target for CorMedix Inc (CRMD)

Shares of CorMedix Inc (NASDAQ:CRMD) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus target price of $4.50 for the company and are forecasting that the company will post ($0.08) earnings per share for the current quarter, according to Zacks. Zacks has also assigned CorMedix an industry rank of 66 out of 257 based on the ratings given to its competitors.

Separately, Roth Capital reissued a “buy” rating and issued a $6.00 price target on shares of CorMedix in a research note on Thursday.

CRMD traded down $0.03 during midday trading on Friday, hitting $1.62. 6,964,858 shares of the company traded hands.

CorMedix (NASDAQ:CRMD) last posted its quarterly earnings data on Wednesday, November 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.05). The business had revenue of $0.37 million for the quarter, compared to analyst estimates of $0.05 million.

CorMedix Company Profile

CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.

Featured Story: Consumer Price Index (CPI)

Get a free copy of the Zacks research report on CorMedix (CRMD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with's FREE daily email newsletter.

Leave a Reply